Liquidia Technologies Highlights Its Transformative PRINT® Technology at the 12th International Nanomedicine and Drug Delivery Symposium

RESEARCH TRIANGLE PARK, N.C.--()--Liquidia Technologies today announced that it will highlight the transformative attributes of the company’s PRINT® (Particle Replication In Non-Wetting Templates) technology at the 12th International Nanomedicine and Drug Delivery Symposium (NanoDDS) in Chapel Hill, NC at the Carolina Club from October 6 – 8, 2014. NanoDDS is a key annual event for researchers developing next-generation delivery vehicles that can make diagnostics more sensitive and drugs more effective.

Neal Fowler, Chief Executive Officer at Liquidia, will participate along with five other distinguished guests in a panel discussion titled How to Advance Nanomedicines From Lab to Marketplace on October 7 from 9:30 – 10:30am.

Also on October 7, Benjamin Yerxa, Ph.D., Chief Scientific Officer at Liquidia, will give an oral presentation in a special session titled Applied Nanomedicine taking place from 9:00-9:30am. The title of Dr. Yerxa’s oral presentation is Commercialization of PRINT® Technology.

Liquidia will also present two posters at this symposium on October 6th. They are as follows:

  • Gabe Fawcett, B.S., Senior Associate Scientist at Liquidia, will present a poster (#19) titled Next Generation Multivalent PRINT® Nanoparticle Vaccine Targeting Pneumococcal Disease.
  • Marquita Lilly, M.S., Scientist at Liquidia, will present a poster (#51) titled PRINT® Nanoparticle Vaccine Carrying Bacterial Polysaccharide and Protein Antigens Induces Enhanced B- and T-Cell (IL-17) Immunity.

The PRINT technology is an innovative, highly tunable and scalable particle engineering process that allows Liquidia to precisely tailor particle size, shape, charge, hydrophobicity, and composition of vaccines with the goal of optimizing a vaccine’s ability to elicit the desired immune response. By using a broad range of matrix materials formulated with active antigens and adjuvants, Liquidia has leveraged its PRINT technology to define particles of specific sizes and shapes that appear to have superior effects on humoral and cellular immune responses.

Liquidia is harnessing the unique capabilities of its PRINT technology to find innovative solutions that can address many of the challenges often encountered in vaccine development with the ultimate goal of creating safe and efficacious vaccines that can provide the broadest possible protection for a global population.


Liquidia Technologies, founded in 2004, is a privately held biotechnology company located in Research Triangle Park, North Carolina. By leveraging precise fabrication techniques of the semiconductor industry, Liquidia has become the only company in the world with the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape, or composition using a unique particle engineering and manufacturing platform known as the PRINT® (Particle Replication In Non-Wetting Templates) technology. This unique ability to precisely engineer particles enables scientists to explore new product frontiers that, until now, have been out of reach for the life sciences industry. Liquidia and its partners are currently exploring the application of this novel technology to develop products in several high growth areas such as vaccines, pulmonology and oncology. In addition to the development of its own products, Liquidia licenses the PRINT particle technology and its cGMP manufacturing capabilities to support proprietary programs advanced by collaborators. For more information, please go to


Liquidia Media Contact:
Michael Parks, 484-356-7105